220997-97-7

Upstream product

• 472958-69-3 3,4-difluorophenyl isocyanide 
• 472958-42-2 (+)-5-ethyl-5-hydroxy-3-iodo-2-(prop-2-ynyl)-2,5,6,9-tetrahydro-8-oxa-2-aza-benzocycloheptene-1,7-dione 
• 219832-71-0 4-(2-ethyl[1,3]dioxolan-2-yl)-2-methoxypyridine 
• 87121-53-7 1-(2-chloropyridin-4-yl)propan-1-one 
• 220998-01-6 3-(3-benzyloxymethyl-2-methoxy-pyridin-4-yl)-3-hydroxy-pentanoic acid 
• 250347-75-2 (R)-3-hydroxy-3-(3-hydroxymethyl-2-methoxypyridin-4-yl)pentanoic acid 
• 500726-35-2 (+)-5-ethyl-5-hydroxy-1-methoxy-5,9-dihydro-8-oxa-2-aza-benzocyclohepten-7(6H)-one 
• 221054-70-2 (+)-(5R)-5-Ethyl-5-hydroxy-2,5,6,9-tetrahydro-8-oxa-2-aza-benzocycloheptene-1,7-dione 
• 186668-51-9 tert-butyl 3-{3-[(benzyloxy)methyl]-2-methoxy-4-pyridinyl}-3-hydroxypentanoate 
• 472958-49-9 (-)-3-hydroxy-3-[2-methoxy-3-methoxymethoxymethyl-6-(trimethylsilanyl)pyridin-4-yl]pentanoic acid 
• 472958-46-6 (E)-3-[2-methoxy-3-methoxymethoxymethyl-6-(trimethylsilanyl)pyridin-4-yl]pent-2-enoic acid ethyl ester 
• 472958-47-7 (R)-3-(2-Methoxy-3-methoxymethoxymethyl-6-trimethylsilanyl-pyridin-4-yl)-pentane-1,3-diol 
• 472958-62-6 (E)-3-[2-methoxy-3-methoxymethoxymethyl-6-(trimethylsilanyl)pyridin-4-yl]pent-2-enoic acid methyl ester 
• 472958-64-8 (+)-trans-{3-ethyl-3-[2-methoxy-3-methoxymethoxymethyl-6-(trimethylsilanyl)pyridin-4-yl]oxiran-2-yl}methanol 

Relevant academic research and scientific papers

Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them

A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them

A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues

The compound of the formula wherein the substituents are defined as in the specification and its non-toxic, pharmaceutically acceptable salts which are useful for the treatment of viral infections, parasitic diseases and the treatment of cancer.

Asymmetric total synthesis of (20R)-homocamptothecin, substituted homocamptothecins and homosilatecans

An efficient asymmetric synthesis of a key DE lactone pyridone intermediate in the synthesis of homocamptothecin is reported. The synthesis is scalable and features a Stille coupling and a Sharpless asymmetric epoxidation as the key steps. The key intermediate has been parleyed into homocamptothecin and an assortment of fluorinated homocamptothecins and homosilatecans (7-silylhomocamptothecins), thereby providing the first asymmetric entry to this important new class of antitumor agents.

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins

Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone. Combining pronounced inhibitory activity of topoisomerase I (Topo I) with enhanced plasma s

Homocamptothecins: Synthesis and antitumor activity of novel E-ring- modified camptothecin analogues

Homocamptothecin (hCPT), a camptothecin (CPT) analogue with a seven membered β-hydroxylactone which combines enhanced plasma stability and potent topoisomerase I (Topo I) mediated activity, is an attractive template for the elaboration of new anticancer a